Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|October 1, 2006
Oral isotretinoin therapy linked to abnormalities in serum lipid, transaminase levels
Abnormality of triglyceride values was most severe in patients during treatment compared with baseline measures.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
2
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
3
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
4
Jenny Hsiao, M.D., says HS biologics need time to work | Fall Clinical Derm 2026
5